However when tested in whole blood to mimic the in vivo situation, the activity of both inhibitors decreased ~100-fold largely due to binding to albumin, resulting in a loss of the potency and thus the selectivity of these inhibitors. The high binding of ABT-263 to albumin highlights the necessity to monitor carefully patients for potential drug interactions.
Introduction
The induction of apoptosis by targeting of BCL2 proteins is one of the most promising therapeutic approaches in various malignancies including CLL. CLL is generally considered incurable, although chemotherapy, radiotherapy and antibody-therapy are all applied to slow down the progression of the disease in aggressive cases of CLL.
Therefore, less toxic and more efficient therapies are urgently required for this very common leukemia. CLL cells display very high levels of BCL2 and are dependent on BCL2 expression for their survival. Anti-apoptotic BCL2 family proteins, including BCL2, BCL-X L , MCL1 and BCL2A1, inhibit apoptosis by sequestering pro-apoptotic BCL2-homology domain 3 (BH3) containing proteins, like BIM, PUMA or BAX/BAK.
The interaction of anti-apoptotic BCL2 family members with these proteins occurs via a hydrophobic groove on the protein surface, into which BH3 domain-containing proteins can bind (1, 2) . Dependent on the structure of the hydrophobic groove and of the BH3 domain, this binding can be very tight and very specific. Upon inhibition of BCL2 proteins, the pro-apoptotic binding partners are released and induce the release of cytochrome c from mitochondria into cytosol, resulting in caspase-dependent apoptosis.
Several small molecule BCL2-inhibitors have been developed that mimic BH3 peptides and target the hydrophobic groove on BCL2 proteins (3) (4) (5) . Amongst these obatoclax, gossypol and ABT-263 are currently in early clinical trials e.g. for CLL and NonHodgkin's lymphoma. However, more detailed mechanistic studies have highlighted that of all these potential BCL2-antagonists probably only ABT-737 and ABT-263 are specific BCL2 family antagonists (6, 7) . Many other putative BCL2-antagonists seem to exert other major effects, which could lead to unwanted non-mechanism based toxicities (6, 7) .
Thus at the present time we propose that only ABT-737 or ABT-263 can be used in either the laboratory or clinic to evaluate both the therapeutic potential and mechanism based toxicity of specifically inhibiting anti-apoptotic BCL2 family members. ABT-737 was initially discovered in the Abbott laboratories using very elegant nuclear magnetic resonance-based screening, chemical synthesis and structure based-design (4) . caused a rapid induction of apoptosis in many cell lines and exerted potent anti-cancer activity in various animal models either alone or more frequently in combination.
However as ABT-737 was rapidly metabolized, had a short half-life and was not orally bioavailable, it was modified in three key positions, resulting in the synthesis of ABT-263, which is both more metabolically stable and orally bioavailable (8) .
In both early clinical trials and animal studies the major dose-limiting mechanism-based toxicity of ABT-263 is a transient thrombocytopenia due to apoptosis of platelets, whose survival is dependent on BCL-X L (9) . Owing to their similar structure and binding affinities, ABT-737 and ABT-263 are often used interchangeably, and both display very high binding affinities to BCL2, BCL-w and BCL-X L , but only weak binding to MCL1 or BCL2A1 (4, 8) . Therefore, high expression of MCL1 or BCL2A1 has been found to confer resistance to ABT-737 (6, (10) (11) (12) . Previous studies have shown that ABT-737 rapidly induces apoptosis in purified CLL cells at nanomolar concentrations in vitro (4, 13, 14) . Although separate studies on both ABT-737 and ABT-263 have been carried out, to our knowledge there are no published studies directly comparing ABT-263 and ABT-737. In this study, to mimic the clinical situation, CLL cells were incubated with ABT-737 and ABT-263 in a whole blood assay. Under these conditions, the sensitivity of CLL cells to both compounds was reduced by ~100-fold due to a combination of higher cell densities in blood and significant albumin binding.
.
Material and Methods

Reagents
ABT-737 was provided by S. Rosenberg (Abbott Laboratories, Abbott Park, IL) and ABT-263 was provided by G. Shore (GeminX, Montreal, Canada). ABT-263 was synthesized by published methods (8, 15) and its purity was 95.1% as assessed by HPLC and a correct mass of m/z=975. After the start of this study a commercial source of ABT-263 also became available (Selleck Chemicals Co.,Shanghai, China). Essentially identical results were obtained with both sources of ABT-263 (data not shown). Bovine serum albumin (BSA) was from Sigma (Sigma Aldrich, Poole, United Kingdom), CD5-PE and CD19-FITC antibodies from Dako Cytomation (Dako Cytomation, Ely, United Kingdom), rabbit anti-BAK antibody was from Upstate (Upstate Biotechnology, Lake Placid, NY), Annexin-APC and tetramethylrhodamine ethyl ester (TMRE) were from Invitrogen (Invitrogen, Paisley, United Kingdom). Caspase-3 antiserum was provided by Dr. Sun (MRC Toxicology Unit).
Cell culture
Peripheral blood samples from CLL patients were obtained with patient consent and local ethical committee approval. Unless otherwise indicated, lymphocytes were purified and cultured in RPMI 1640 medium supplemented with 10% FCS and 2 mM L-glutamine (all from Life Technologies, Inc, Paisley, United Kingdom) at 1 x 10 6 cells ml -1 . CLL cells were incubated with ABT-737 or ABT-263 at 37°C and apoptosis assessed as previously described (14) . Alternatively, blood from patients was incubated with ABT-737 or ABT-263 at 37°C in 48-well plates as described previously (16) . Murine embryonic fibroblasts were cultured in DMEM medium (Life Technologies, Inc) supplemented with 10% FCS and 2 mM L-glutamine. 
Release of cytochrome
F-Dextran release assay
The release of fluorescein-dextrans (F-dextrans) from liposomes was measured as described previously (17) . Briefly, liposomes containing 7% cardiolipin were generated by the extrusion method and internally loaded with fluorescein-dextran (10 kD) (Invitrogen). They were incubated with recombinant proteins (human origin); BAX, N/C-BID (cleaved form of BID), BCL-X L with and without ABT-737 or ABT-263 (0.04-5 µM). After incubation, the assay mix was filtered to collect released dextrans in the filtrate and the fluorescence was measured against a detergent solubilized sample, which gave 100 % release. 
Immunoprecipitation
Fluorescence Polarization Assay
The binding affinity of ABT-737 and ABT-263 to human serum albumin (HSA) was measured using fluorescence polarization assay (FPA) as described previously (18) . 
Results
ABT-263 is less potent than ABT-737 in inducing apoptosis in CLL cells
In this study we compared the in vitro efficacy of two very closely related BCL2-antagonists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was ~4-fold more potent (Fig. 1A) . This higher susceptibility of CLL cells to ABT-737 was observed in all 21 samples examined (Fig. 1B) . These initial findings indicate that despite their apparent structural similarity ( To gain insight into the mechanism of ABT-263 induced cell death, we asked whether ABT-263 induced activation of apoptotic signalling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was again less potent than ABT-737 ( Fig. 3A and B) . Since unstimulated CLL cells express very little or no BCL-X L , the main target of ABT-263 and ABT-737 in CLL cells is BCL2, where they act by displacing pro-apoptotic BH3 domain-containing proteins. To investigate the activity of both compounds at the level of BCL2-inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263. Previously, we had shown that small amounts of BAK but not BAX were sequestered by BCL2 (12) . In agreement with our earlier study, BAK was again shown to be associated with BCL2 (Fig. 3C ). ABT-737 (10 or 100 nM) efficiently displaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nM) were required to induce release of BAK (Fig. 3C ). These data demonstrate that while both compounds have the ability to displace BAK from BCL2, ABT-263 is less efficient than ABT-737. In addition, we recently described that ABT-737 induces a novel paradigm of apoptosis in CLL cells involving all the normal characteristics of apoptosis accompanied by a rupture of the outer mitochondrial membrane (14) . Here we show that ABT-263 (100 nM) induced similar ultrastructural changes to ABT-737 (10 nM), including condensed chromatin, rupture of the outer mitochondrial membrane and loss of mitochondrial matrix density ( Fig. 3D and E) . Finally, ABT-263 induced apoptosis was completely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. 3F) , suggesting that ABT-263, like ABT-737 (6, 7), is a specific inhibitor of BCL2 proteins. Taken together, our data indicate that both compounds induce cell death by a similar mechanism involving displacement of BAK from BCL2 and activation of the intrinsic apoptotic pathway accompanied by rupture of the outer mitochondrial membrane.
The efficiency of ABT-263 and ABT-737 decreased in whole blood
In order to more closely mimic the in vivo situation, we compared the efficacy of the two compounds to induce apoptosis using whole blood from CLL patients rather than the standard cell culture medium. At 4 h, ~100-fold higher concentrations of both BCL2-antagonists were required to induce apoptosis in CLL cells in blood compared to cell culture medium (compare Figs. 1A and 4A ). The reduced potency of ABT-263 as compared to ABT-737 was even more pronounced in whole blood than in purified CLL cells. To investigate whether longer exposure times increased apoptosis, we incubated blood with different drug concentrations for up to 12 h. Whereas lower concentrations of ABT-737 (0.1 -1 μM) induced apoptosis at longer exposure times, ABT-263 only induced apoptosis at concentrations > 1 μM even when incubated for up to 12 h (Fig.   4B ).
Binding to albumin confers resistance to ABT-737 and ABT-263
As these data clearly show that CLL cells lose their striking sensitivity towards these inhibitors in the presence of whole blood, we next investigated which components of whole blood caused the loss of sensitivity to ABT-737 and ABT-263. In CLL, the white blood cell count in peripheral blood is regularly > 1 x 10 8 /ml, much higher than the concentration of cells typically used in vitro (1 x 10 6 /ml). To examine the influence of cell density on the sensitivity to BCL2-antagonists, CLL cells were incubated at different densities in culture medium. Although a 10-fold higher cell density than used in our standard culture did not significantly affect sensitivity, higher cell densities similar to those found in the blood of CLL patients (1-5 x 10 8 cells/ml) required higher concentrations of ABT-737 and ABT-263 to induce cell death ( Fig. 5A and B) .
Furthermore, we investigated whether the high serum content in blood compared to the 10% serum routinely used in cell culture medium affected susceptibility to BCL2-antagonists. Higher serum concentrations (50% FCS) induced resistance to ABT-737 and ABT-263, while lower serum concentrations (1% FCS) markedly sensitized CLL cells to apoptosis induced by either drug (Fig. 5C and D) . Similar responses to the presence of serum were found in cell lines, where higher serum concentrations resulted in decreased sensitivity to ABT-737 and ABT-263 (data shown to referees). During the initial chemical synthesis of ABT-737, it was recognized that the lead compounds were largely inactivated by the presence of serum and the major inactivating component was due to binding to domain III on human serum albumin (HSA) (19) . Consequently ABT-737 was designed, in part, to overcome this high binding to albumin, which adversely affected the binding to BCL-X L (4, 19) . To investigate whether the inhibitory effect of serum on apoptosis induced by ABT-737 or ABT-263 was due to the presence of albumin, 3% bovine serum albumin (BSA), corresponding to the concentration of albumin in 50% FCS, was added. Notably, addition of BSA induced a similar shift in the concentrationresponse to ABT-737 or ABT-263 as 50% FCS (Fig. 5C and D) . Since the sensitization by low FCS concentrations (1%) could be completely reversed by addition of albumin, lack of growth factors or cytokines following serum withdrawal cannot account for the sensitization to BCL2-antagonists. These results strongly suggest that albumin was the predominant factor in serum responsible for resistance to ABT-263 or ABT-737.
ABT-263 binds more tightly than ABT-737 to albumin
To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay. There are two main drug binding sites on HSA, site 1 on subdomain IIA and site 2 on subdomain IIIA (20, 21) . Using two different probes, dansyl sarcosine, which binds to site 2, and dansyl L-glutamate, which binds to site 1, we were able to distinguish binding of ABT-737 and ABT-263 to the different HSA subdomains. Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-IIIA than ABT-737 (Fig. 6A) . Notably, the half maximal inhibitory concentration (IC 50 ) of ABT-263 in this assay was 37 μM, which was lower than that displayed by the positive control naproxen (51 μM) which binds strongly to that site (18) , indicating a very tight interaction between HSA and ABT-263. While ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC 50 of 145 μM (positive control phenylbutazone: 49 μM) (18) (Fig. 6B ). These data demonstrate that ABT-263 has a higher albumin binding capacity than ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.
Discussion
Due to their ability to directly induce apoptosis, BCL2-inhibitors offer a great potential for cancer therapy, especially for malignancies with high BCL2 expression and a dependency on BCL2 expression for survival (22) . CLL cells were previously reported to be highly sensitive to BCL2 inhibition and treatment with ABT-737 (4, 13, 14, 23). To our knowledge we now show for the first time that freshly isolated CLL cells display a similar, albeit somewhat lower, nanomolar sensitivity to ABT-263 (Fig. 1) . ABT-263 induced a rapid activation of the intrinsic pathway of apoptosis that was absolutely dependent on Bax and Bak. Induction of apoptosis in CLL cells by ABT-263 was accompanied by chromatin condensation together with rupture of the outer mitochondrial membrane and a decreased mitochondrial matrix density (Fig. 3) , ultrastructural features virtually identical to those we had previously observed with ABT-737 and described as a novel paradigm of apoptosis (14) . These results further emphasize the similar activities of ABT-737 and ABT-263 in agreement with recent studies (15, 24) and strongly support the hypothesis that they both act to induce apoptosis in CLL cells by an identical mechanism. We emphasize the importance of studying these effects with ABT-263, as this is the compound, not ABT-737, currently being used in clinical trials.
Most importantly our data demonstrate that isolated CLL cells lose their striking nanomolar sensitivity to both ABT-737 and ABT-263 in the presence of whole blood. The EC 50 of CLL cells to ABT-263 in whole blood is >10 μM at 4 h of treatment (Fig. 4A) .
Notably, the maximal plasma concentrations of ABT-263 achieved in clinical trials with a 250 mg daily dosing schedule are around 5 μM (25), indicating that the concentrations in whole blood might not be optimal in the current phase I and phase II clinical trials for ABT-263. In our study we identify two factors that affect the efficacy of these BCL2-inhibitors: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-737 and ABT-263 that we observed in whole blood as compared to standard cell culture (Fig. 5 A-B) . The impact of cell density on drug sensitivity may be a particular problem in certain microenvironments, such as lymph nodes, where drugs encounter even higher cell densities than in the peripheral blood. We also describe that these BCL2-inhibitors are extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. 5 C-D) . Albumin is the most abundant protein in human plasma and is well known to bind a wide range of drugs as well as endogenous molecules (18, 20, 21) . ABT-263 bound to albumin much more strongly than ABT-737 (Fig. 6) and it bound to site 2 on subdomain IIIA more strongly than naproxen (18) , indicating a very tight interaction between albumin and ABT-263.
Extensive binding to albumin may have profound effects on the absorption, distribution, metabolism and excretion of molecules, often meaning that higher doses need to be administered in vivo (26, 27) . The high albumin binding of ABT-263 may act a reservoir of the drug, resulting in a long half life. However, the high albumin-binding might also be a source of potential drug interactions as ABT-263 may be displaced by other drugs that bind extensively to albumin, thus increasing the potential efficacy and toxicity of ABT-263. Additionally, our data indicate that patients with a hypoalbuminemia might react differently to ABT-263 and conditions where albumin levels are affected need to be closely monitored for toxicities.
It is interesting to consider the higher albumin binding of ABT-263 compared to ABT-737 in relation to their structures. During the development of ABT-263, the 4-chlorobiphenyl, arylnitro and dimethylamino groups of ABT-737 (Fig. 1C, positions 1, 2 and 3 , respectively) were modified primarily to decrease metabolism and increase oral bioavailability without losing cellular activity. However, the dimethylamino group in ABT-737, which had been specifically designed to reduce binding to albumin (19) , is replaced by a morpholino group in ABT-263 (8) . In this regard the introduction of a morpholino group at this position in the development of ABT-737 (compound 77R in (19) ) was much less effective than a dimethylamino group in reducing the deactivating effects of serum on the binding affinity to BCL-X L and it was concluded that a charged species in this position was particularly effective in reducing serum binding (19) . In the absence of serum, the lead compounds in the ABT-737 series with the dimethylamino or morpholino group showed similar binding affinities to BCL2 proteins, whereas in the presence of serum, the morpholino group resulted in a complete loss of binding to BCL-X L . These results indicate the potential deleterious effects of a morpholino group at this position and indicate that although ABT-263 clearly shows important biological activity the possibility that substitution of another group in this position may yield a BCL2 family inhibitor with more favorable pharmacokinetics.
To exclude any effects of serum or albumin, we wished to test the susceptibility of CLL cells to ABT-737 and ABT-263 in a serum-free system. However, culture of CLL cells in the complete absence of any serum is not feasible because it is too toxic and cells underwent spontaneous apoptosis (data not shown). Using a biochemical F-dextran release assay in liposomes, we found that both compounds have the same capacity to target BCL2 proteins, in line with previously published data reporting a similar affinity of both compounds for BCL2 and BCL-X L (4, 28) . However, the reduced activity of ABT-263 was also observed in permeabilized cells in the absence of any serum or albumin ( 
